title: Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
abstract: BACKGROUND
  Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy.
  
  
  METHODS
  A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software.
  
  
  RESULTS
  Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients.
  
  
  CONCLUSIONS
  Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.
authors.affiliation: Division of Breast Surgery, St. Luke's-Roosevelt Hospital Center, New York, NY, USA; Division of Breast Surgery, Beth Israel Medical Center, New York, NY, USA.
authors.forename: Juhi
authors.initials: J
authors.lastname: Asad
authors.forename: Allyson F
authors.initials: AF
authors.lastname: Jacobson
authors.forename: Alison
authors.initials: A
authors.lastname: Estabrook
authors.forename: Sharon Rosenbaum
authors.initials: SR
authors.lastname: Smith
authors.forename: Susan K
authors.initials: SK
authors.lastname: Boolbol
authors.forename: Sheldon M
authors.initials: SM
authors.lastname: Feldman
authors.forename: Michael P
authors.initials: MP
authors.lastname: Osborne
authors.forename: Kwadwo
authors.initials: K
authors.lastname: Boachie-Adjei
authors.forename: Wendy
authors.initials: W
authors.lastname: Twardzik
authors.forename: Paul I
authors.initials: PI
authors.lastname: Tartter
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D003657:Decision Making; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000188:drug therapy; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D015203:Reproducibility of Results; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen